Psychiatry AtlasMedication guide · United States

Antipsychotic medicine

Paliperidone (Invega, Invega Sustenna, Invega Trinza, Invega Hafyera)

Generic name
paliperidone; paliperidone palmitate in long-acting injections
Brand names
Invega; Invega Sustenna; Invega Trinza; Invega Hafyera
Medication class
Antipsychotic medicine
Forms covered
Invega extended-release tablets; Invega Sustenna monthly injection; Invega Trinza three-monthly injection; Invega Hafyera six-monthly injection

Article updated: 2026-10-24 · Sources last checked: 2026-11-05

Medication Safety Alerts

Look-alike / sound-alike name

  • Invega can be confused with Intuniv.

FDA Boxed Warning

Invega extended-release tablets; Invega Sustenna monthly injection; Invega Trinza three-monthly injection; Invega Hafyera six-monthly injection.

Paliperidone increases the risk of death in older adults with dementia-related psychosis. Invega tablets and the Sustenna, Trinza and Hafyera injections are not approved for dementia-related psychosis.

Paliperidone treats schizophrenia and, with selected products, schizoaffective disorder. Oral tablets and monthly, three-monthly and six-monthly injections have different indications and transition rules.

What to expect: Treatment aims to reduce symptoms such as hallucinations, delusions and disorganized thinking.

Warning signs · Medicine forms
Sources last checked:
2026-11-05

What is this medicine used for?

FDA-approved uses

  • Schizophrenia — Adults and adolescents ages 12–17. Age and kidney-specific dosing.Invega extended-release tablets.
  • Schizophrenia — Adults. Longer intervals require the specified prior stabilization.Invega Sustenna monthly injection; Invega Trinza three-monthly injection; Invega Hafyera six-monthly injection.
  • Schizoaffective disorder — Adults. Alone or adjunctive to mood stabilizers or antidepressants.Invega extended-release tablets; Invega Sustenna monthly injection.

What should I expect?

Treatment aims to reduce symptoms such as hallucinations, delusions and disorganized thinking. Improvement is assessed over time; sleepiness or stiffness can appear before the full benefit is clear.

Longer-interval injections are maintenance options after the required earlier treatment, rather than an immediate starting choice. Track symptoms, daily functioning and adverse effects at follow-up.

How do I take it safely?

Swallow oral extended-release tablets whole, once daily, with or without food. Do not split, crush or chew them. An empty shell in stool can be normal; severe narrowing of the digestive tract needs assessment before oral use.

Injections are administered by a healthcare professional. Monthly, three-monthly and six-monthly products have different approved uses and prerequisites. Three- and six-monthly treatment requires prior stabilization on the specified earlier injection regimen. Do not change products or intervals yourself.

Kidney function affects suitability and dose. Follow weight, blood pressure, blood sugar, cholesterol, movement symptoms and prolactin-related symptoms such as menstrual changes or milk production. Heart-rhythm tests or blood counts may be needed. Review other medicines that affect heart rhythm, alertness or blood pressure; avoid alcohol.

Discuss pregnancy and breastfeeding; late-pregnancy antipsychotic exposure can affect a newborn’s movement or cause withdrawal symptoms. Older adults with dementia-related psychosis have an increased risk of death; these products are not approved for that use.

Do not double a forgotten oral dose. Contact the clinic promptly about any missed injection: re-start instructions depend on the product and how much time has passed. Plan stopping with the prescriber.

A previous allergic reaction to risperidone can also rule out paliperidone.

Do not use this product after a known allergy to its active medicine or ingredients; tell the pharmacist about previous medication reactions.

What side effects should I know about?

  • Restlessness or stiffness, sleepiness, dizziness, weight gain and injection-site discomfort.

Tell your prescriber about effects that are persistent, troublesome, or interfere with daily life.

Which warning signs need help?

  • The boxed warning concerns increased death in older adults with dementia-related psychosis; these products are not approved for that use.
  • High fever with rigid muscles and confusion can be neuroleptic malignant syndrome and needs emergency care. Seek emergency care for a seizure, collapse, serious breathing difficulty, facial or throat swelling, or suspected overdose. Fainting with an irregular heartbeat, severe swallowing difficulty or a painful prolonged erection also needs urgent assessment.
  • Report new involuntary movements promptly: tardive dyskinesia may persist after treatment. New fever or infection, severe thirst or frequent urination, and prolactin-related symptoms need review. Heart-rhythm changes, low blood pressure, seizures and impaired temperature control are other important risks.

What else should I know to stay safe?

  • Kidney function affects suitability and dose. Review heart-rhythm risks and interacting medicines; monitor weight, blood pressure, blood sugar, cholesterol, movement symptoms and prolactin-related symptoms. Avoid alcohol. Allergy to paliperidone, risperidone or product ingredients rules out use.
  • Longer-interval injections require specified prior treatment and are not interchangeable. Missed injections or stopping need a clinic-directed plan because restarting requirements differ. Oral tablets may be unsuitable with severe narrowing of the digestive tract.
  • Discuss pregnancy and breastfeeding; late-pregnancy exposure can cause newborn movement or withdrawal symptoms.

Urgent help and crisis support · Emergency & Crisis Resources (US)

What can help day to day?

  • Seeing an empty tablet shell in the stool can be normal: the medicine has already been released.
  • A three- or six-month injection can reduce visits for doses, but ongoing symptom and physical-health follow-up still matters.
  • Different injection intervals do not mean every product has the same approved uses. The longer-interval products are for schizophrenia.

How does it work?

Paliperidone changes how brain cells respond to dopamine and serotonin, two chemical messengers. It blocks selected receptors, the proteins that receive these messages. These actions are thought to contribute to benefit, but researchers do not fully understand how they produce improvement in symptoms.

Explore medication science

How was this medicine developed?

Oral Invega was approved in 2006, followed by monthly Invega Sustenna in 2009 and three-monthly Invega Trinza in 2015. Longer delivery intervals changed convenience, while retaining product-specific eligibility and monitoring requirements.

How do I say the name?

Paliperidone: pal-ee-PER-i-done. Capital letters show the stressed syllable.

Medicine forms and official information

Match the full name, release type and route on your prescription. Different formulations need their own prescribing instructions; do not switch or substitute them yourself.

Sources and References

Sources support the U.S. products described here. Product instructions can differ; use the information supplied with your own medicine.

  1. Invega (paliperidone) extended-release tablets: prescribing information — mechanism explanation

    Scope: Mechanism explanation only. Source sections checked: 11 Description; 12.1 Mechanism of Action; 12.2 Pharmacodynamics; 12.3 Pharmacokinetics..

  2. Paliperidone: FDA approval history
  3. Paliperidone: patient medicine information
  4. Invega Sustenna (paliperidone palmitate): prescribing information — mechanism explanation

    Scope: Mechanism explanation only. Source sections checked: 12.1 Mechanism of Action; 12.3 Pharmacokinetics..

  5. Invega Trinza prescribing information
  6. Invega Hafyera prescribing information
  7. Sustenna FDA approval history
  8. Trinza and Hafyera FDA application
  9. Invega: Package Insert / Prescribing Information / MOA
  10. Risperidone: prescribing information
  11. Paliperidone: verified neutral parent, PubChem CID 115237
  12. ISMP List of Confused Drug Names
  13. Invega, Invega Sustenna, Invega Trinza and Invega Hafyera FDA prescribing information (January 2025)
  14. Schizophrenia
  15. NIMH: Understanding psychosis
  16. Cultural Formulation in Diagnosis and Cultural Concepts of Distress - Improving Cultural Competence - NCBI Bookshelf
  17. Frequently Asked Questions about Labeling for Prescription Medicines | FDA
  18. Tardive dyskinesia: MedlinePlus Medical Encyclopedia
  19. NIMH: Mental Health Medications

Giving medicine safely to children: family guide (PDF, 3 pages)

How information is checked

Was this article helpful?

Was this article helpful?

Sends your choice, article identifier, edition and optional issue to Psychiatry Atlas. No name, email or medical details are requested. Daily network codes help prevent spam; hosting may process technical information. This is not a promise of anonymity. Privacy details.

Enable JavaScript to send feedback.

Suggest a missing topic or describe a correction. Please keep personal medical information out of website feedback.

Back to top